

Patient Name

DOB MRN

Physician

Physician's Orders INFLIXIMAB (RENFLEXIS/INFLECTRA/

CSN REMICADE) - ADULT, OUTPATIENT, COREWELL HEALTH INFUSION CENTER Page 1 to 6

□ Interval: INDU	s not otherwise specified below: CTION – Every 14 days x 2 treatm ITENANCE – Every 56 days	ents (maintenance treat	ment starts on day 42)
Duration: ☐ Until date: ☐ 1 year ☐# of Tr			
Anticipated Infusion Da	teICD 10 Codewith E	Description	
Height((cm) Weight(kg) Allerg	ies	
Provider Specialty ☐ Allergy/Immunology ☐ Cardiology ☐ Gastroenterology ☐ Genetics	 ☐ Infectious Disease ☐ Internal Med/Family Practice ☐ Nephrology ☐ Neurology 	□ OB/GYN □ Other □ Otolaryngology □ Pulmonary	☐ Rheumatology☐ Surgery☐ Urology☐ Wound Care
Site of Service CH Blodgett (GR) CH Gerber CH Greenville	☐ CH Helen DeVos (GR) ☐ CH Lemmen Holton (GR)	☐ CH Ludington☐ CH Pennock	☐ CH Reed City ☐ CH Zeeland
Appointment Request	ts		
Status: Future Infusion and p	pointment Request e, Expected: S, Expires: S+365, Sched. Toleral possible labs. Verify that all INDUCTION/LOAD AINTENANCE DOSES. idelines		
	DER REMINDER 3 ABDA (RENFLEXIS) or INFLIXIMAB-DYYB (IN	IFLECTRA) OR INFLIXIMAB (RE	EMICADE):
Premedicatio	n is not required, but can be considered for the	prevention of subsequent infusion	on reactions.
	inFLIXimab-abda (RENFLEXIS) or inFLIXimab all patients must have a TB test completed.	o-dyyb (INFLECTRA) or inFLIXim	nab (REMICADE) infusion, AND
All patients sh	nould have HBV screening prior to initiating; HE	BV carriers (during and for severa	al months following therapy)
INFLIXIMAB- MAINTENAN and 6. The S and continues	IDER REMINDER 21 ABDA (RENFLEXIS) or INFLIXIMAB-DYYB (IN CE: **CAUTION - ENSURE APPROPRIATE T pectrum Health Therapy Plan for INDUCTION s every 8 weeks. **ENSURE APPROPRIATE T	IMING OF THERAPY. Usual Ind contains weeks 0 and 2. The MA	luction therapy is administered weeks 0, 2, AINTENANCE therapy plan starts WEEK 6
Satety Parameters an	d Special Instructions		
Verify all IND	TY PARAMETERS AND SPECIAL IN UCTION/LOADING DOSES given prior to start	of MAINTENANCE DOSES	
	TY PARAMETERS AND SPECIAL IN 3 VIRUS SURVEILLANCE AND MAINTENANC serology.		en prior to treatment. Refer to specialist as

TUBERCULOSIS SURVEILLANCE AND MANAGEMENT RECOMMENDATIONS: Screen prior to treatment and annually for



ONC SAFETY PARAMETERS AND SPECIAL INSTRUCTIONS 5

continuing therapy. Treat latent infection prior to starting therapy.

INFLIXIMAB (RENFLEXIS/INFLECTRA/ REMICADE) - ADULT, OUTPATIENT, COREWELL HEALTH INFUSION CENTER (CONTINUED) Page 2 to 6

Patient Name
DOB
MRN
Physician
CSN

Lak	os			
			Interval	Duration
	~	Complete Blood Count w/Differential	□ Once	□ Until date:
			□ Every 56 days	□ 1 year
		Status: Future, Expected: S, Expires: S+184, URGENT, Clinic Col	loct Blood Blood Vanous	□# of Treatments
		Status, Future, Expected. 3, Expires. 3+104, ONGENT, Cliffic Col	lect, blood, blood, verious	
	~	Basic Metabolic Panel (BMP)	Once	1 treatment
		Status: Future, Expected: S, Expires: S+365, URGENT, Clinic Col	lect, Blood, Blood, Venous	
-	✓	Hepatic Function Panel (Liver Panel)	□ Once	□ Until date:
			□ Every 56 days	□ 1 year
				□# of Treatments
		Status: Future, Expected: S, Expires: S+365, URGENT, Clinic Col	lect, Blood, Blood, Venous	
-		Haratitia D. Confess Anti-usa Laval		
	~	Hepatitis B Surface Antigen Level	□ Once □ PRN	□ Until date: □ 1 year
				□ 1 year □ # of Treatments
		Status: Future, Expected: S, Expires: S+365, URGENT, Clinic Col	lect, Blood, Blood, Venous	# of frediments
-		Hepatitis B Core Total Antibody Level	□ Once	□ Until date:
		Tropantis B Gore Total/Milibody Level	□ PRN	□ 1 year
				□ # of Treatments
		Status: Future, Expected: S, Expires: S+365, URGENT, Clinic Col	lect, Blood, Blood, Venous	
	✓	Comprehensive Metabolic Panel (CMP)	□ Once	
			□ Every 56 days	•
		Status: Eutura Expected: S. Evpiros: S+265 LIDCENT Clipia		□# of Treatments
		Status: Future, Expected: S, Expires: S+365, URGENT, Clinic Collect, Blood, Blood, Venous		
_				
		range For Patient To Have Id Tb Skin Test Administ ior To Therapy Or Annually	ered And Read Or Serun	n Tb Screening Lab
		ONC PROVIDER REMINDER 28	Once	1 treatment
		Arrange for patient to have intradermal TB skin test (tuberculin PP	D) screening performed and read	d prior to initiating therapy and
		annually.		
		TB Screen (Quantiferon Gold)	Once	1 treatment
		Status: Future, Expected: S, Expires: S+365, URGENT, Clinic Col	lect, Blood, Blood, Venous	
			Interval	Duration
		Labs:	□ Everydays	□ Until date:
			Once	□ 1 year
				# of Treatments

Confidentiality of this medical record shall be maintained except when use or disclosure is required or permitted by law, regulation, or written authorization by the patient.



INFLIXIMAB (RENFLEXIS/INFLECTRA/ **REMICADE) - ADULT, OUTPATIENT,** COREWELL HEALTH INFUSION CENTER (CONTINUED) Page 3 to 6

Patient Name DOB MRN

Physician

CSN

Vitals

Vital Signs

Routine, PRN, Starting S For Until specified, Vital Signs Monitoring: Obtain vital signs (patient temperature, blood pressure and pulse) upon arrival, after start of medication, upon discontinuing infusion and before the patient departs the facility. However, if patient has an acute reaction with preceding dose, monitor vitals every 10 minutes for 30 minutes then every 30 minutes and for 30 minutes after

Nursing Orders

ONC NURSING COMMUNICATION 1

INFLIXIMAB-ABDA (RENFLEXIS) OR INFLIXIMAB (REMICADE) OR INFLIXIMAB-DYYB (INFECTRA):

✓ ONC NURSING COMMUNICATION 100 May Initiate IV Catheter Patency Adult Protocol

Hypersensitivity Reaction Adult Oncology Protocol

S Until discont'd

Routine, Until discontinued Starting when released for 24 hours HYPERSENSITIVITY REACTIONS:

Discontinue the medication infusion immediately.

Activate emergency response for severe or rapidly progressing symptoms. Where available consider calling RAP and have crash cart available. Call 911 or code team (if applicable) as needed for an absence of pulse and respirations. Refer to site specific emergency response policy.

Stay with patient until symptoms have resolved.

Initiate/Continue Oxygen to maintain SpO2 greater than 90% and discontinue Oxygen Therapy to maintain SpO2 above 90%

For severe or rapidly progressing hypersensitivity reaction symptoms, monitor vital signs and pulse oximeter readings every 2 to 5 minutes until the patient is stable and symptoms resolve.

Document medication infusing and approximate dose received at time of reaction in the patient medical record. Document allergy to medication attributed with causing reaction in patient medical record. Complete Adverse Drug Reaction form per Pharmacy Clinical Policy.

Treatment Parameters

ONC MONITORING AND HOLD PARAMETERS 3

May proceed with treatment if hepatitis B core antibody and surface antigen labs have been resulted prior to the first dose, and the results are negative.

ONC MONITORING AND HOLD PARAMETERS 4

May proceed with treatment if tuberculosis screening test with either TB Screen blood test (QuantiFERON® Gold Plus) or TB skin test have been resulted prior to first dose and within one year for continuing therapy, and the results are negative.







INFLIXIMAB (RENFLEXIS/INFLECTRA/ REMICADE) - ADULT, OUTPATIENT, COREWELL HEALTH INFUSION CENTER (CONTINUED) Page 4 to 6

Patient Name
DOB
MRN
Physician
CSN

re-Medic	re-Medications		
	acetaminophen (TYLENOL) tablet 650 mg 650 mg, Oral, Once, Starting S, For 1 Doses		
	diphenhydrAMINE (BENADRYL) capsule Dose: 25 mg 50 mg Oral, Once, Starting S, For 1 Doses		
	methylPREDNISolone sodium succinate (SOLU-Medrol) injection Dose:		
Additiona	I Pre-Medications		
	Pre-medication with dose:		
	Pre-medication with dose:		





INFLIXIMAB (RENFLEXIS/INFLECTRA/ REMICADE) - ADULT, OUTPATIENT, COREWELL HEALTH INFUSION CENTER (CONTINUED) Page 5 to 6

Patient Name			
DOB			
MRN			
Physician			
CSN			

nduction	Treatment
~	Select Either Infliximab-abda (Renflexis) Or Infliximab-dyyb (Inflectra) Or Infliximab (Remicade)
	inFLIXimab-abda (RENFLEXIS) IVPB (PREFFERED FORMULARY PRODUCT)
	Dose:
	□ 3 mg/kg
	□ 5 mg/kg
	□ 10 mg/kg
	□ mg/kg
	Intravenous, Administer over 2 Hours, Once, Starting S+30 Minutes, For 1 Doses
	Infuse over at least 2 hours. FOR THE FIRST DOSE AND FOR PATIENTS WITH A HISTORY OF INFUSION REACTION: Begin infusion at 10 mL/hr for 15 minutes, then 20 mL/hr for 15 minutes, then 40 mL/hr for 15 minutes then 80 mL/hr for 15 minutes, then 150 mL/hr for 30 minutes, then 250 mL/hr until infusion complete.
	FOR SUBSEQUENT INFUSIONS: If patient tolerates infusion, may infuse over 2 hours without titration.
	inFLIXimab-dyyb (INFLECTRA) IVPB
	Dose:
	□ 3 mg/kg
	□ 5 mg/kg
	□ 10 mg/kg
	□ <u>□</u> mg/kg
	Intravenous, Administer over 2 Hours, Once, Starting S+30 Minutes, For 1 Doses
	Infuse over at least 2 hours. FOR THE FIRST DOSE AND FOR PATIENTS WITH A HISTORY OF INFUSION REACTION: Begin infusion at 10 mL/hr for 15 minutes, then 20 mL/hr for 15 minutes, then 40 mL/hr for 15 minutes then 80 mL/hr for 15 minutes, then 150 mL/hr for 30 minutes, then 250 mL/hr until infusion complete.
	FOR SUBSEQUENT INFUSIONS: If patient tolerates infusion, may infuse over 2 hours without titration.
	inFLIXimab (REMICADE) IVPB
	Dose:
	□ 3 mg/kg
	□ 5 mg/kg
	□ 10 mg/kg
	□ mg/kg
	Intravenous, Administer over 2 Hours, Once, Starting S+30 Minutes, For 1 Doses
	Infuse over at least 2 hours. FOR THE FIRST DOSE AND FOR PATIENTS WITH A HISTORY OF INFUSION REACTION: Begin infusion at 10 mL/hr for 15 minutes, then 20 mL/hr for 15 minutes, then 40 mL/hr for 15 minutes then 80 mL/hr for 15 minutes, then 150 mL/hr for 30 minutes, then 250 mL/hr until infusion complete.
	FOR SUBSEQUENT INFUSIONS: If patient tolerates infusion, may infuse over 2 hours without titration.





INFLIXIMAB (RENFLEXIS/INFLECTRA/ C Page 6 to 6

Patient Name		
DOB		
MRN		
Physician		
CSN		

EMICADE) - ADULT, OUTPATIENT,	
OREWELL HEALTH INFUSION CENTER	(CONTINUED

<u>Mainte</u>	nance Treatment
	Select Either Infliximab-abda (Renflexis) Or Infliximab-dyyb (Inflectra) Or Infliximab (Remicade)
	inFLIXimab-abda (RENFLEXIS) IVPB (PREFFERED FORMULARY PRODUCT)
	Dose: 3 mg/kg 5 mg/kg 10 mg/kg 10 mg/kg Intravenous, Administer over 2 Hours, Once, Starting S+30 Minutes, For 1 Doses Infuse over at least 2 hours. FOR THE FIRST DOSE AND FOR PATIENTS WITH A HISTORY OF INFUSION REACTION: Begin infusion at 10 mL/hr for 15 minutes, then 20 mL/hr for 15 minutes, then 40 mL/hr for 15 minutes then 80 mL/hr for 15 minutes, then 150 mL/hr for 30 minutes, then 250 mL/hr until infusion complete. FOR SUBSEQUENT INFUSIONS: If patient tolerates infusion, may infuse over 2 hours without titration.
	inFLIXimab-dyyb (INFLECTRA) IVPB
	Dose: 3 mg/kg 5 mg/kg 10 mg/kg mg/kg mg/kg 10 mg/kg mg/kg Minutes, For 1 Doses Infuse over at least 2 hours. FOR THE FIRST DOSE AND FOR PATIENTS WITH A HISTORY OF INFUSION REACTION: Begin infusion at 10 mL/hr for 15 minutes, then 20 mL/hr for 15 minutes, then 40 mL/hr for 15 minutes then 80 mL/hr for 15 minutes, then 150 mL/hr for 30 minutes, then 250 mL/hr until infusion complete. FOR SUBSEQUENT INFUSIONS: If patient tolerates infusion, may infuse over 2 hours without titration.
	inFLIXimab (REMICADE) IVPB Dose: 3 mg/kg 5 mg/kg 10 mg/kg

Telephone order/Verbal order documented and read-back completed. Practitioner's initials _

NOTE: Unless Order is written DAW (dispense as written), medication may be supplied which is a generic equivalent by nonproprietary name.



EPIC VERSION DATE: 12-14-23